Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir as treatments for COVID-19 in high-risk patients.
Dimitrios ParaskevisM GkovaK MellouG GerolymatosΝ PsalidaK GkolfinopoulouE G KostakiS LoukidesA KotanidouA SkoutelisE ThiraiosG SaroglouD ZografopoulosD FilippouElias A MossialosT ZaoutisM GagaS TsiodrasA AntoniadouPublished in: The Journal of infectious diseases (2023)
Collectively, these real-world findings suggest that although the risks of hospitalization and death due to COVID-19 have been reduced, antivirals can provide additional benefits to members of highly vulnerable patient populations.